Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications
Higher body mass index is associated with lower drug concentrations in patients with inflammatory bowel disease treated with ustekinumab but not vedolizumab.
Journal: Inflammatory bowel diseases
Published: April 14, 2026
Higher Anti-Drug Antibody Levels to Anti-Tumor Necrosis Factor Therapies Are Associated with Treatment Failure in Patients with Inflammatory Bowel Disease.
Journal: Journal of clinical medicine
Published: December 10, 2025
Artificial intelligence detection of endoscopic moderate-to-severe ulcerative colitis: a novel tool to enhance clinical trial recruitment.
Journal: iGIE : innovation, investigation and insights
Published: December 04, 2025
Lower drug clearance of adalimumab is associated with proactive therapeutic drug monitoring and mucosal healing in patients with inflammatory bowel disease.
Journal: European journal of gastroenterology & hepatology
Published: November 04, 2025
Proactive Compared to Reactive Therapeutic Drug Monitoring Is Associated with Less Treatment Failure in Patients with Inflammatory Bowel Disease Treated with Adalimumab.
Journal: Digestive diseases and sciences
Published: October 19, 2025
Postpartum nonsteroidal anti-inflammatory drug exposure does not increase risk for flare in patients with inflammatory bowel disease.
Journal: Annals of gastroenterology
Published: August 18, 2025
Serum proteomics in paediatric inflammatory bowel disease from a case-control study: biomarker discovery and ulcerative colitis-Crohn's disease differentiation.
Journal: EBioMedicine
Published: June 18, 2025
Long-term Outcomes of Patients with Crohn's Disease Treated with Risankizumab.
Journal: Inflammatory bowel diseases
Published: April 29, 2025
Antisense to human CD39 dysregulates immune metabolism in inflammatory bowel disease.
Journal: Cellular & molecular immunology
Published: October 11, 2024
Proactive Therapeutic Drug Monitoring of Ustekinumab Is Associated With Increased Drug Persistence in Patients With Inflammatory Bowel Disease.
Journal: Inflammatory bowel diseases
Published: July 14, 2024
A Multicenter Study to Assess Avoidant/Restrictive Food Intake Disorder in Patients with Inflammatory Bowel Disease.
Journal: Inflammatory bowel diseases
Published: June 13, 2024
Proactive Therapeutic Drug Monitoring Is Associated With Increased Drug Persistence in Patients With Inflammatory Bowel Disease Treated With Intravenous Vedolizumab.
Journal: Inflammatory bowel diseases
Published: April 18, 2024
Last Updated: 09/26/2026